Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference

Rhea-AI Summary

Synaptogenix, Inc. (OTC: SNPX) announced its participation in the Winter Wonderland Conference from February 16-19, 2021. Dr. Alan Tuchman, CEO, and Dr. Daniel Alkon, CSO, will present on February 17 at 11:30 am EDT and hold one-on-one meetings on February 18 and 19. The conference, featuring curated presentations, aims to connect emerging biopharmaceutical opportunities with institutional investors. Synaptogenix focuses on developing neuro-regenerative therapies, especially Bryostatin-1 for Alzheimer's and other rare diseases, with FDA Orphan Drug Designation for Fragile X syndrome.

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Alan Tuchman M.D., Chief Executive Officer, and Dr. Daniel Alkon M.D., Chief Scientific Officer, will host a group presentation at the MicroCap Rodeo's Winter Wonderland Conference on Wednesday, February 17^th, 2021 at 11:30 am EDT, and hold one-on-one meetings on February 18^th and 19^th.

The Winter Wonderland "Best Ideas from the Buyside" conference will be held February 16^th through 19^th, 2021 with 25-minute virtual presentations on the 16th and 17^th, and one-on-ones for qualified institutional investors on the 18th and 19^th.

The conference is 100% curated by leading micro-cap buy-side fund managers. Please visit the event website at https://microcaprodeo.com to register for the conference and schedule a one-on-one meeting with Synaptogenix.

About Synaptogenix, Inc.

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel neuro-regenerative drug therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease, and preclinical studies for rare diseases such as Fragile X syndrome, Niemann-Pick Type C disease, and Rett syndrome, multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,600 people in cancer and AD studies, thus creating a large safety data base that will further inform clinical trial designs.

Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com. 

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Contact information:
Investors and Media

Investor Relations
Brett Maas
Hayden IR
brett@haydenir.com
(646)536-7331

Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com

View original content:http://www.prnewswire.com/news-releases/synaptogenix-to-participate-in-the-winter-wonderland--best-ideas-from-the-buy-side-conference-301227465.html

SOURCE Synaptogenix, Inc.

FAQ

When is Synaptogenix presenting at the Winter Wonderland Conference?

Synaptogenix will present on February 17, 2021, at 11:30 am EDT.

What are the dates of the Winter Wonderland Conference?

The Winter Wonderland Conference runs from February 16 to February 19, 2021.

Who are the key speakers from Synaptogenix at the conference?

Dr. Alan Tuchman, CEO, and Dr. Daniel Alkon, CSO, will be the key speakers.

What is Synaptogenix's focus in biopharmaceuticals?

Synaptogenix specializes in therapies for neurodegenerative diseases, including Alzheimer's disease.

What is Bryostatin-1 and its significance for Synaptogenix?

Bryostatin-1 is Synaptogenix's lead therapeutic candidate for Alzheimer's and has Orphan Drug Designation for Fragile X syndrome.

Where can I register for the Winter Wonderland Conference?

You can register for the conference at https://microcaprodeo.com.